Liminal Biotech
Cardiometabolic diseases represent one of the largest and fastest-growing global health challenges, driving substantial morbidity, mortality, and healthcare costs worldwide. Despite available therapies, many patients remain inadequately treated. At Liminal Biotech, we are addressing an unmet medical need within the cardiometabolic space.
Project summary
Host university
University of Copenhagen
Funding pr. year
DKK 5,35M
Duration
Three years
Expected outcome
Viable startup that can raise seed or a Series A investment
Project leaders
See who leads Liminal Biotech on its mission to make novel therapies addressing patients suffering from cardiometabolic diseases.